87.09MMarket Cap-13280P/E (TTM)
4.180High4.050Low76.99KVolume4.180Open4.180Pre Close318.04KTurnover4.81%Turnover RatioLossP/E (Static)20.88MShares4.90052wk High-3.22P/B6.67MFloat Cap2.51052wk Low--Dividend TTM1.60MShs Float4.900Historical High--Div YieldTTM3.11%Amplitude2.510Historical Low4.130Avg Price1Lot Size
OS Therapies Stock Forum
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose
OS Therapies Incorporated (NYSE:OSTX) ("OS Therapies" or "the Company"), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today announced that the last patient (Patient #41) enrolled in the AOST-2121 clinical trial (NCT04974008) of OST-HER2 in recurred, resected Osteosarcoma (OS) - has received its last treatment dos...
$Serve Robotics (SERV.US)$
Osteosarcoma is relatively rare, 1,000 cases per year, but more prevalent among children, making it more serious.
Other information:
2% of all childhood cancers
8th most common cancer in children
Most common bone malignancy
$Australian Oilseeds Holdings (COOT.US)$
$Rocket (RKT.US)$
No comment yet